PYC Therapeutics (ASX:PYCDA) - Stock Price, News & Analysis

PYCDA Stock Overview

A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. More details

PYCDA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 15.56% per year

Risk Analysis

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

PYC Therapeutics Limited Competitors

Clinuvel Pharmaceuticals

ASX:CUV

AU$680.3m

Aroa Biosurgery

ASX:ARX

AU$224.2m

Imugene

ASX:IMU

AU$312.4m

Race Oncology

ASX:RAC

AU$237.8m

Price History & Performance

Summary of all time highs, changes and price drops for PYC Therapeutics
Historical stock prices
Current Share Price	AU$1.90
52 Week High	AU$1.96
52 Week Low	AU$1.70
Beta	0.60
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	2.70%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	PYCDA	AU Biotechs	AU Market
7D	n/a	-4.9%	0.4%
1Y	n/a	9.9%	16.9%

Return vs Industry: Insufficient data to determine how PYCDA performed against the Australian Biotechs industry.

Return vs Market: Insufficient data to determine how PYCDA performed against the Australian Market.

Price Volatility

Is PYCDA's price volatile compared to industry and market?
PYCDA volatility
PYCDA Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.0%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.4%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: PYCDA's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: Insufficient data to determine PYCDA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2001	n/a	Rohan Hockings	pyctx.com

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder; and PYC-003, which is indicated to treat autosomal dominant polycystic kidney disease. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders.

PYC Therapeutics Limited Fundamentals Summary

How do PYC Therapeutics's earnings and revenue compare to its market cap?
PYCDA fundamental statistics
Market cap	AU$835.23m
Earnings (TTM)	-AU$37.73m
Revenue (TTM)	AU$22.06m

37.9x

P/S Ratio

-22.1x

P/E Ratio

Is PYCDA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PYCDA income statement (TTM)
Revenue	AU$22.06m
Cost of Revenue	AU$0
Gross Profit	AU$22.06m
Other Expenses	AU$59.78m
Earnings	-AU$37.73m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.081
Gross Margin	100.00%
Net Profit Margin	-171.02%
Debt/Equity Ratio	0%

How did PYCDA perform over the long term?

See historical performance and comparison